ABG Sundal Collier AB (”ABGSC”) has notified Oncopeptides AB (publ) (“Oncopeptides” or the ”Company”) that stabilisation measures regarding the Company’s shares have been effected.

As previously announced, ABGSC is acting as stabilisation manager in connection with the offer to acquire shares in the Company and the listing on Nasdaq Stockholm (the ”Offering”), and ABGSC may, acting as a stabilisation manager, effect transactions aimed at supporting the market price of the shares at levels above those which might otherwise prevail in the open market.

This information is such that Oncopeptides is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was released for public disclosure, through the agency of the contact persons above, on March 2, 2017 at 7.00 p.m (CET).

For more information please visit: www.oncopeptides.se/en/abg-sundal-collier-ab-abgsc-has-notified-oncopeptides-ab-publ-oncopeptides-or-the-company-that-stabilisation-measures-regarding-the-company-ipo